Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510309 · ClinicalTrials.gov registry record · Phase 2
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
A Phase 2 study of Lymphoma and Marginal Zone Lymphoma, sponsored by Gottfried von Keudell, MD PhD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06510309 is a Phase 2 study of Lymphoma and Marginal Zone Lymphoma that is actively recruiting participants, run by Gottfried von Keudell, MD PhD. The registered enrollment target is 33 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06510309, a Phase 2 study of Lymphoma and Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Gottfried von Keudell, MD PhD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Rituximab
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2026-02-11 |
| Est. Completion | 2031-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510309
The ClinicalTrials.gov registry entry for NCT06510309 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is Gottfried von Keudell, MD PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT06510309 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06510309 about?
NCT06510309 is a clinical study titled "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma". The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma (MZL). The names of the study drugs involved in this study are: * Venetoclax (a type of inhibitor) * Rituximab (a type of antibody)
What is the current status of trial NCT06510309?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2026-02-11. Estimated completion is 2031-10-01.
What conditions does trial NCT06510309 study?
This clinical trial studies the following conditions: Lymphoma, Marginal Zone Lymphoma, MZL.
What interventions are being tested in trial NCT06510309?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG).
Who is sponsoring clinical trial NCT06510309?
This trial is sponsored by Gottfried von Keudell, MD PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510309 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.